Full-Time
Senior Manager
Program Management and Governance, Revenue Technology
Updated on 8/23/2026
Becton Dickinson
10,001+ employees
Global medical devices and diagnostics provider
No salary listed
Washington, USA + 36 more
More locations: Kansas, USA | Pennsylvania, USA | Oregon, USA | Delaware, USA | Iowa, USA | California, USA | Vermont, USA | Wyoming, USA | Connecticut, USA | Texas, USA | Montana, USA | Florida, USA | Nevada, USA | Arizona, USA | Mississippi, USA | Tennessee, USA | Virginia, USA | Arkansas, USA | Minnesota, USA | Colorado, USA | Franklin Lakes, NJ, USA | Nebraska, USA | Utah, USA | Kentucky, USA | Maryland, USA | Maine, USA | Massachusetts, USA | Oklahoma, USA | Missouri, USA | Ohio, USA | Indiana, USA | Louisiana, USA | Michigan, USA | Illinois, USA | Alabama, USA | Idaho, USA
Remote
Remote role with travel up to 30% domestically and internationally for workshops, forums, and key engagements.
Bachelor's
 Business & Strategy (2) |
|---|
| , |
Get referred to Becton Dickinson
See people who can refer or advise you
- A bachelor's degree in Business, Engineering, Information Systems, or a related field, or equivalent professional experience.
- At least 7 years of experience in program management, transformation delivery, consulting, operations, or technology-focused roles within large, global organizations.
- Proven experience leading multi-workstream initiatives with complex dependencies and senior-level visibility.
- Demonstrated experience establishing and owning governance, including decision forums, decision rights, and vendor governance, rather than solely coordinating programs.
- Demonstrated ability to operate effectively and influence without authority in a matrixed environment.
- Willingness and ability to travel up to 30% domestically and internationally for in-person workshops, program forums, and key engagements.
- Own the overarching Revenue Technology strategic roadmap across CPQ, CLM, and Bids & Tenders, including portfolio governance and innovation alignment.
- Align the portfolio with emerging innovation and next-generation capabilities.
- Lead program governance across the global CPQ, CLM, and Bids & Tenders implementation, ensuring consistent standards and delivery discipline across workstreams.
- Establish governance frameworks, standards, and decision rights while enabling approved local and business-unit variation.
- Oversee the program roadmap, business readiness, risk management, and milestone tracking end to end.
- Drive a consistent operating cadence across AMER and international workstreams.
- Lead key decision forums and steering committees and own executive stakeholder reporting on roadmap, trade-offs, and delivery outcomes.
- Manage cross-functional stakeholder alignment and executive reporting across Commercial, IT/Digital Solutions, Finance, Procurement, and senior leadership.
- Own and lead the Revenue Technology governance model, including decision rights, escalation paths, and review cadences.
- Steward the strategy-to-budget linkage and hold partners accountable for committed outcomes.
- Own vendor relationships, contract governance, and license management across Revenue Technology platforms.
- Partner with Procurement and Finance on vendor strategy, contracting, renewals, usage forecasting, and budget controls.
- Identify opportunities for license optimization, consolidation, cost avoidance, and vendor risk mitigation.
- Own the single-backlog intake framework and triage demand across regions and business units using Now, Next, and Later prioritization.
- Maintain integrated roadmaps for CPQ, CLM, and Bids & Tenders initiatives from concept through delivery and value realization.
- Identify cross-program dependencies, downstream impacts, and organizational-readiness factors.
- Ensure commitments are made through disciplined intake and governance processes.
- Drive execution across multiple concurrent initiatives spanning CPQ, CLM, and Bids & Tenders platforms, data, and artificial intelligence enablement.
- Manage program plans, milestones, risks, and resources in partnership with the shared TDS Program Manager.
- Establish and run ceremonies, sprints, demos, and releases across workstreams.
- Plan and facilitate in-person requirements workshops and program forums, owning the output and the path from design through requirements to release.
- Coordinate onboarding of new business into the product model from intake through requirements to release.
- Coordinate change-management and business-readiness activities across regions and workstreams to ensure adoption.
- Monitor adoption, cycle time, data quality, cost management, and other success metrics.
- Track progress using objective data and performance indicators and adjust plans and priorities based on results.
- Ensure initiatives deliver measurable and sustained business value through value-realization practices.
- Serve as the integrator between business leaders and delivery teams across the Revenue Technology portfolio.
- Translate complex initiatives into clear, outcome-focused narratives for executive audiences.
- Influence executive decisions through fact-based insights, structured recommendations, and clear articulation of trade-offs.
- Experience supporting CPQ, CLM, quote-to-cash, or commercial technology platforms.
- Experience coordinating delivery with internal IT or shared services and third-party vendors or system integrators.
- Experience owning vendor governance, licensing, and budget defense for a technology portfolio.
- Experience working across agile, waterfall, or mixed delivery models.
- Strong analytical skills with the ability to translate data and insights into actionable program decisions.
- Ability to simplify complexity and communicate clearly with technical and non-technical audiences.
BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
Get referred to Becton Dickinson
See people who can refer or advise you
Simplify's Take
What believers are saying
- BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
- Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
- Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.
What critics are saying
- FDA classified BD’s intraosseous recall Class I on August 17, 2026.
- The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
- Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.
What makes Becton Dickinson unique
- BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
- BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
- BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 10%1 year growth
↑ 10%2 year growth
↑ 10%Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".
BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.
BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."
Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.
BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.